396 – Breast cancer screening: understanding risk, deciding when to start, and more
In a Nutshell
Breast cancer screening saves lives by shifting detection to earlier, more treatable stages, with annual mammography from age 40 reducing mortality ~40% in average-risk women and MRI adding substantial benefit for those at elevated risk. Most preventable deaths stem from under-screening—about one-third of eligible women are not up to date on mammography, and over 95% of those qualifying for MRI never receive it—rather than from aggressive biology that evades detection. The practical solution is early formal risk assessment (by ~age 25), knowing breast density, and selecting a personalized protocol of annual DBT mammography (plus MRI for high-risk) executed consistently at a high-quality center.
These notes were generated by AI and may contain inaccuracies.
The Drive podcast focuses on translating the science of longevity into accessible content for everyone. The goal is to provide the best content in health and wellness without relying on paid ads, made possible by members who receive exclusive member-only content and benefits.
This episode addresses the central question of how to give yourself the best possible chance of not dying from breast cancer. The full episode and detailed show notes are available to everyone regardless of premium subscriber status.
About 1 in 8 women will develop invasive breast cancer over their lifetime. In the United States, roughly 42,000 women die every year from this disease, making it one of the leading causes of cancer death behind only lung, colorectal, and pancreatic. Despite effective screening tools, many women still have questions about when screening should start, how often to do it, and what factors matter.
Even women who have looked at guidelines often come away more confused because guidance differs between organizations and has shifted over time. This confusion has real consequences because breast cancer screening works. Cancers found through screening are more likely to be caught early before spread when treatment is easier and outcomes are better.
The stage shift matters enormously. When breast cancer is caught at stage 1, the 10-year survival is over 96%. By stage 4, 5-year survival is only around 30%. Women who screen regularly are up to 40% less likely to die from the disease.
Screening is not without trade-offs. Overdiagnosis of lesions that would never progress to cancer can increase healthcare burden with no real benefit and remains an area of ongoing uncertainty. These considerations do not negate the core point that screening is one of the most effective tools for reducing breast cancer mortality.
If optimizing for individual risk of dying from breast cancer rather than population efficiency or societal cost, the default should be to err on the side of more effective screening and certainly not less. Part of the answer is biology—some breast cancers are more aggressive, grow quickly, spread early, and can be difficult to intercept even with very good screening. Back of the napkin math suggests somewhere around 7 to 10% of cases are unlikely to be caught even with perfect screening.
A major and much more solvable part of the problem is under-screening. Roughly a third of women over 40 have not had a mammogram in the past 2 years. Even among women aged 50 to 74 where evidence is most universally agreed upon, about 20% are not up to date. Under-screening has two layers: most women are not getting routine mammography at the right time, and some women are getting screened but not with the right strategy for their risk profile.
According to criteria laid out by major screening guidelines, at least 9% of women meet the threshold for breast MRI as part of their screening protocol, yet the actual utilization rate is just 0.4%. This is a pure execution failure—we already know who these high-risk women are and already have a tool that materially improves detection.
The goal is to provide a practical framework for smarter screening that starts with understanding actual risk and helps make informed decisions about when to start, how often to screen, and what imaging to use. Population guidelines form a great starting point but are not the finish line.
A recent survey found that roughly 50% of women aren't sure when to start mammography. The guidance has shifted multiple times over the past two decades, most recently in 2024. Several organizations publish screening recommendations and do not all agree.
Every woman should have a formal risk assessment by about the age of 25. If average risk, annual mammography should begin at 40. If high-risk, MRI and eventually mammography may be needed much earlier, and screening should continue for as long as willing to pursue treatment if cancer were found. This composite comes from groups like the American Cancer Society, the National Comprehensive Cancer Network, and the American College of Radiology.
The US Preventive Service Task Force (USPSTF) recommends mammography only every other year for average risk women aged 40 to 74 with no explicit recommendation for high-risk women. USPSTF guidance tends to inform insurance coverage decisions.
Population-level guidelines are created by looking at large studies and evaluating the optimal strategy for maximizing cancer detection while minimizing false positives across millions of women, taking into account societal cost. When moving from populations to actual people, personalization matters.
When thinking about personalizing screening for any cancer, the first question is what is my baseline risk? Given that risk, how much false positive burden am I willing to tolerate in exchange for potentially earlier detection? Which screening plan, both modality and frequency, best matches both of these objectives? This is about deciding whether the default plan actually fits you.
Most women who develop breast cancer do not have one dramatic obvious risk factor. It is far more common to have several smaller risk factors that together add up to a higher risk. Risk assessment is only useful if it happens early enough to change the plan—you do not want to find out at age 42 that you should have started MRI years earlier. This is why some groups recommend formal risk assessment by age 25.
Breast cancer is overwhelmingly more common in women—1 in 8 versus 1 in about 750 for men. Men can develop this as well. Age is one of the strongest breast cancer risk factors overall. The median age of diagnosis is around 62 and the vast majority of breast cancers are diagnosed after age 40. Risk accumulates over time.
Mutations in genes like BRCA 1 and BRCA 2 are the most recognized inherited breast cancer risk factors. They can substantially increase risk and often shift that risk earlier in life. In the general population, only about 1 in 400 people carry a pathogenic mutation in BRCA 1 or BRCA 2, though prevalence is higher in some groups including people of Ashkenazi Jewish ancestry. There are also other important genes.
Family history captures more than just known single gene mutations. It is a proxy for high-impact mutations like BRCA mutations but also reflects the cumulative effect of lower penetrant genetic variants, shared environmental exposures, and other inherited factors that no single genetic test currently covers. Having multiple first or second degree relatives with breast cancer can substantially increase risk.
Lack of family history does not automatically equate to low risk. Some families are small. Some relatives may have died young of other causes. Some mutations that increase breast cancer risk can show up in the family as other cancers like prostate or pancreatic cancer rather than an obvious pattern of breast cancer. The absence of a family history of breast cancer does not guarantee average risk.
In the US, Black women are more likely to be diagnosed younger and with more aggressive subtypes, which has implications for how early and how aggressively screening should be considered.
Prior chest radiation, such as radiation treatment for Hodgkin's lymphoma in adolescence or early adulthood, carries great risk. Cumulative high-dose exposure, particularly around the time when breast tissue is still developing, carries the greatest risk. A single chest X-ray or CT delivers a tiny fraction of the dose used in cancer treatments, and evidence that occasional routine chest imaging meaningfully increases breast cancer risk is very weak at best.
Dense breasts are associated with a somewhat higher baseline risk of breast cancer. Dense tissue makes mammograms harder to interpret because both dense tissue and tumors appear white on the image. Density is not just a biological risk factor—it is one of the main reasons the most common screening test becomes less effective.
Breast density is fairly heritable, roughly 60 to 70%. If a mother or grandmother was told she had dense breasts, that is worth knowing. The FDA now requires imaging centers to notify women of breast density, typically reported with the BI-RADS density category. A and B are considered non-dense while C and D are considered dense. About 50% of screening-age women have dense breast tissue.
Factors pointing toward higher risk include earlier onset of menarche, later menopause, never having had a full-term pregnancy, having a first pregnancy after age 40, and not breastfeeding. Individually, none of these typically change the screening plan on its own, but they contribute slightly to overall risk especially when several are present together.
Modifiable risk factors include alcohol use, obesity, poor metabolic health, and physical inactivity. These do not change screening protocol based on these alone, but they can shift risk and are factors to actually do something about.
Risk is usually the sum of multiple inputs, some large, some small, that together determine whether someone is truly average risk, somewhat above or below average, or clearly high risk. Calculators like Tyrer-Cuzick combine family history, personal risk factors, and breast density to estimate 10-year and lifetime risk. Most screening guidelines classify lifetime risk above 20% as high risk, though factors such as ancestry may shift that threshold.
In the US, about 10% of screening mammographies lead to a callback for additional testing, but only about 5% of those callbacks end in a cancer diagnosis. For every thousand women who undergo a screening mammogram, about 100 will be called back because something looked abnormal, but about 95 of those 100 will not actually have cancer. More than half the women screened annually for 10 years will experience at least one false positive result.
The most common harms from breast cancer screening are not major physical injuries from the test itself, but the anxiety and uncertainty that comes from a return visit for more imaging. When a callback leads to an earlier cancer diagnosis, it is obviously worthwhile, but when most callbacks do not end in cancer, screening strategy must be thought through carefully for each individual woman.
The higher the baseline risk, the easier it is to justify accepting more false positives in exchange for finding more cancer earlier. If very high risk, such as carrying a BRCA mutation or having a combination of factors that pushes lifetime risk well above average, then a more aggressive strategy is easy to defend. If truly average risk or even lower than average risk, the decision is based largely on preference.
Breast imaging is a toolkit consisting of different varieties of mammography, MRI, and ultrasound. Some are best for routine screening, while others are more appropriate for follow-up on an abnormal finding or as a supplemental option in higher risk women.
Mammograms use low-dose x-rays to look for breast cancer and for most average risk women remain the starting point. Mammography is particularly good at detecting calcifications such as those seen in ductal carcinoma in situ (DCIS). DCIS is sometimes called stage zero breast cancer—the abnormal cells are still confined to the ducts rather than invading surrounding tissue. Estimates suggest that somewhere between 25 and 60% of DCIS cases may eventually become invasive cancer.
In 2000, the FDA approved the first full field digital mammography system. In 2011, digital breast tomosynthesis (DBT), commonly referred to as 3D mammography, was rolled out. DBT takes multiple images from different angles to create a more layered view of the breast. This results in better cancer detection with lower recall rates, particularly for women with dense breasts. DBT is the version of mammography to prioritize, especially for women with dense breasts.
MRI uses magnetic fields and intravenous gadolinium-based contrast to detect abnormal blood flow or tissue behavior that mammography can miss, making it the most sensitive screening tool available. It is better for detecting very small invasive tumors and atypical cancers than any other imaging modality. MRI is generally used in addition to but not instead of mammography. Mammography still does a better job with certain calcifications.
The abbreviated breast MRI takes only 10 to 15 minutes compared to 30 to 60 minutes for the full exam. It preserves nearly all of the sensitivity of the full exam, making it cheaper, faster, and more scalable while still providing dramatically better cancer detection than mammography alone. For women with extremely dense breasts, adding MRI after a negative mammogram cut the rate of interval cancers in half from 5 per thousand to 2.5 per thousand.
Contrast-enhanced mammography (CEM), introduced in 2011, is basically mammography plus intravenous iodine-based contrast. It gives more functional information than a standard mammogram and can be a very reasonable alternative when MRI is unavailable or contraindicated.
Ultrasound uses sound waves rather than radiation or magnetic fields to create images of breast tissue. Handheld ultrasound involves a technician or radiologist moving the probe manually. Automated ultrasound has the machine acquire images more systematically. Both are more operator dependent than mammography or MRI and both carry a higher false positive burden.
In one study, adding physician-performed handheld ultrasound to a standard 2D mammography increased the rate of cancer detection by 4.2 per thousand women screened. A second study paired technician-performed ultrasound with DBT and the detection boost was much smaller, only about 1.1 per thousand. When the base imaging is better or the technician is less experienced, the incremental benefit of ultrasound shrinks.
Handheld ultrasounds allow for real-time visualization, making them an excellent option for getting more clarity on something suspicious seen on other imaging or guiding biopsies. Ultrasound can boost cancer detection over mammography alone, but not to the same extent seen with adding MRI. For average risk women, ultrasound is not a substitute for mammography. For high-risk women, it is not a substitute
For high-risk women, mammography is not a substitute for MRI. The foundation for all women is mammography, ideally digital breast tomosynthesis (DBT). If risk is elevated or if dense breast tissue is likely to reduce the sensitivity of mammography, MRI is the most effective supplemental tool. If MRI is not feasible due to cost, access, or contraindication, contrast-enhanced mammography is the next best option. Ultrasound can add incremental detection, but its benefit is more variable and highly dependent on operator skill and on baseline imaging that it is paired with.
These tools are not interchangeable. They have a clear hierarchy in terms of sensitivity and consistency. The goal is to choose the combination that best matches individual risk.
Regardless of the screening tool chosen, where screening occurs matters. Not every imaging center offers every modality, and not every center has the same level of experience with the tests it offers. Simply having imaging done is not the same as having high-quality imaging done.
For mammography, positioning and complete tissue capture matter. MRI and contrast-enhanced mammography are more standardized, but they still depend on good protocol execution, contrast timing, and experienced interpretation. Ultrasound is the most operator-dependent modality.
A routine mammogram can usually be done well in many places, but the quality of imaging and interpretation still varies. High-volume centers and dedicated breast imaging centers tend to have more experience, better protocols, and more consistent interpretation. For advanced imaging such as MRI, contrast-enhanced mammography, or ultrasound in dense breast tissue, going to a center that performs these studies frequently and has specialized expertise should be strongly considered. The difference is not trivial and in some cases it can directly affect whether a cancer is detected.
Each imaging modality has strengths and weaknesses. Which option is chosen is a personal choice based on risk, preferences, and access.
The USPSTF recommends biennial mammography for average-risk women aged 40 to 74. Most other groups recommend annual mammography starting around age 40 or a hybrid approach with annual screening from 45 to 54 and biennial screening thereafter.
No randomized control trial has ever directly compared annual versus biennial screening with mortality as its primary endpoint. Every interval recommendation is based on modeling studies and observational data.
The most important modeling data come from the Cancer Intervention and Surveillance Modeling Network (CISNET), a consortium of independent modeling groups funded by the National Cancer Institute. CISNET has been commissioned three times to run simulations for the USPSTF, and the task force has leaned heavily on these models to justify biennial mammography recommendations. Other cancer and radiology groups have looked at the same CISNET data to conclude that annual screening is better.
If the question is how to maximize efficiency across an entire population, balancing cost, false positives, and resource utilization, biennial screening is a defensible answer. If the question is what gives an individual woman the best chance of avoiding death from breast cancer, the answer is different.
The argument for biennial mammography traces back to the original 2009 CISNET analysis, which found that biennial screening retained about 81% of the mortality benefit of annual screening with roughly half as many false positives. This was done using data from film-based mammography. The conclusion was not that biennial mammography was best for mortality, but that it offered the best tradeoff between benefit and resource use at a population level.
In 2024, CISNET published its most comprehensive analysis using multiple models and imaging strategies, including both two-dimensional digital mammography and DBT. A secondary analysis showed that annual screening is better for saving lives. When compared to no screening, annual screening of women aged 40 to 79 produced a 42% mortality reduction, while biennial screening produced only a 30% mortality reduction. In absolute numbers, this corresponded to 230 life years gained per thousand women for annual screening versus 165 for biennial.
The cumulative number of false positives is higher for annual screening, but the rate of false positives and benign biopsies per exam is actually lowest with annual screening, likely because the radiologist has a more recent image to compare to, making it easier to distinguish cancerous changes from normal variation.
The case for biennial screening rests on population-level efficiency, not on maximizing the benefits for any individual woman. If the goal is the best chance of not dying from breast cancer, CISNET's own data indicate screening annually.
Among women aged 40 to 84 who developed breast cancer, those screening annually had far fewer interval cancers (11% versus 38% for biennial screeners) and were more likely to have an early-stage diagnosis (76% stage 1 with annual screening versus 56% with biennial).
Taken together, the modeling and observational data support that if the goal is to maximize chances of avoiding death from breast cancer as an individual, annual mammography is the better strategy.
All major studies have focused on mammography. For adding MRI, the most common approach in clinical practice is to alternate the two tests every 6 months rather than stacking them at the same time. The logic is that spacing them out creates a six-month screening interval instead of a 12-month one, giving fast-growing cancers less time to develop between screens.
Evidence comparing stacking versus alternating is limited. One small study found that the combined sensitivity of MRI plus mammography was higher than either test alone, while another found no significant difference. For ultrasound plus mammography, the timing question has essentially never been studied directly. All major ultrasound trials performed both tests simultaneously and annually.
There is no compelling evidence to favor one schedule over another. Alternating every six months may be reasonable for high-risk women who are more likely to develop rapidly growing cancers, but until better prospective data exist, the scheduling decision is more about logistics and personal preference.
All women should screen annually with mammography. If high-risk and getting multiple imaging modalities, alternating them every six months is reasonable, but the evidence is not strong enough to insist on that schedule. The bigger issue is not whether the tests are staggered, but whether both tests are getting done consistently each year.
Risk assessment should be done in the mid-20s. The next question is when to actually start screening. The intuitive assumption is that if screening saves lives, starting earlier should save more of them, but whether earlier screening helps depends on many factors.
The risk for developing breast cancer before age 40 is genuinely low. Only about 5% of breast cancer diagnoses occur in women under 40. The cumulative risk through age 90 is about 13% (the familiar 1-in-8 statistic), but the cumulative risk through age 40 is less than 1%.
Data come from cancer registries that capture all diagnosed cancers, including those found symptomatically and those caught in women who began screening earlier because of elevated risk. Age-incidence curves rise smoothly and continuously through the 30s and 40s with no sharp spike at age 40, indicating the low incidence under 40 is real, not an artifact of under-detection.
There are no randomized trials and no mortality data on screening average-risk women under 40. The best available study examined about 6 million mammograms from facilities across the US, with about 12% from women under 40. Researchers compared cancer detection rates across age groups by whether a woman had at least one risk factor (personal history of breast cancer, family history in a first-degree relative, or dense breasts).
Among women aged 35 to 39 with at least one risk factor, the cancer detection rate was 2.1 per thousand women screened. For average-risk women in the same group with no family history, no personal history, and non-dense breasts, the rate was 0.59 per 1,000—a roughly 3.5-fold difference driven by risk factors, not age alone.
For average-risk women aged 40 to 44, the detection rate was 0.71 per thousand. Women in their late 30s with risk factors were being diagnosed at roughly three times the rate of average-risk women screening in their 40s. Risk factors effectively shift a woman's screening profile forward by a decade.
Once women reach 45 and older, incidence rises enough that detection rates exceed what is seen in women under 40, regardless of risk. Below that threshold, risk factors may matter more than age.
Knowing baseline risk is what makes the difference. The age-40 cutoff for screening makes sense on average, but for women with one or more of the three risk factors (personal history, first-degree family history, or dense breasts), earlier screening may be appropriate. Women diagnosed with breast cancer in their 20s and 30s are disproportionately those who could have been identified as above-average risk earlier.
Breast cancer does not look the same in younger women as in older women. Younger women are much more likely to develop aggressive subtypes. About 20% of breast cancers in women under 40 are triple-negative (the most aggressive form) compared with roughly 6–12% in women over 40. Triple-negative cancers can double in size in under four months, so even annual screening may not catch them in time.
Slower-growing cancers with doubling times closer to a year make up only about a third of cases in women under 40, compared to well over half in older women. For high-risk women, this biology has direct implications for which screening tool to use. Mammography alone may not be enough.
Risk from a BRCA1 mutation is heavily front-loaded. A woman in her late 20s carrying a BRCA1 mutation has a breast cancer risk roughly 100 times that of a non-carrier. By her 30s, it is about 44 times. By her 60s, it drops to about three times. These mutations shift the entire risk curve earlier. Because cancers in younger high-risk women tend to be fast-growing and harder to see on mammography, MRI is the more appropriate screening tool.
One of the three risk factors in the study was breast density. Density cannot be known definitively without imaging. About half of women have dense breasts, and density is higher in younger women. There is a reasonable argument for getting a single baseline mammogram in the 30s, not primarily to find cancer, but to establish whether dense breasts are present. If density is present, that changes the risk profile and may change the screening strategy. This is less about cancer detection and more about risk stratification.
If truly average risk, beginning annual mammography at 40 is well supported, though a baseline mammogram in the 30s may be considered at minimum to establish breast density. If above-average risk, there is a small amount of evidence that mammography in the 30s can be worthwhile. If clearly high risk (known BRCA carrier, strong family history, or prior chest radiation), a more aggressive screening protocol should be started in the 20s or early 30s.
Inflammatory breast cancer is a rare type (roughly 1–5% of all breast cancers) but is aggressive and does not present the way most people expect. There is often no discrete lump. Instead, rapid swelling or heaviness of the breast, redness or rash, warmth, or changes in skin texture or thickness may be noticed. Because these symptoms can look like skin irritation or something relatively benign, diagnosis is frequently delayed.
Normal screening mammography does not rule out inflammatory breast disease—these cancers may not be visible on mammography. A diagnostic workup is necessary if symptoms appear.
Screening tests are designed for women without symptoms. If something new is noticed (a lump, skin changes, nipple discharge, pain that does not resolve), evaluation should be sought rather than waiting for the next scheduled screening. A recent normal screen does not guarantee everything is fine.
The discussion has focused on women because the vast majority of breast cancers occur in women, but men do develop breast cancer. Because men are not routinely screened, symptoms are typically the only path to diagnosis. A new symptom in a man should not be dismissed and should be evaluated.
If screening works so well, why are 42,000 women still dying from breast cancer every year? Part of the answer is biology—some cancers are aggressive enough that they will evade even the best screening. The far larger part is that screening is not being done intelligently enough.
A quarter of eligible women are not up to date on basic mammography. The vast majority of women who qualify for MRI are not getting it. Most women have never had a formal risk assessment. The science and tools exist; the evidence is strong. What is missing is the bridge between what is known and what women are actually doing.
Access to MRI is limited in many areas. Insurance coverage is often tied to USPSTF recommendations, which do not fully address high-risk populations. Imaging quality varies across centers. These system-level factors contribute to under-screening and suboptimal screening.
There is still a great deal within individual control. The four key steps are:
- Complete a risk assessment using a validated risk calculator to obtain a quantitative sense of baseline risk.
- Find out breast density from prior imaging or plan to establish it when beginning screening.
- Choose a cancer screening strategy (both modality and frequency) that matches the level of risk and tolerance for false positives.
- Execute that plan consistently over time.
None of these steps are complicated, but taken together they separate passive screening from intentional, personalized screening. With current technology, breast cancer deaths cannot be reduced to zero, but far too many lives are still being lost because the right tools are applied too late, too inconsistently, or to the wrong people. At the individual level, this problem is more solvable than most realize—if risk is assessed, the right screening strategy is chosen, and screening is actually carried out consistently.
Keep Peter Attia MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
